New Formulations of Local Anaesthetics—Part I by Shipton, Edward A.
Hindawi Publishing Corporation
Anesthesiology Research and Practice
Volume 2012, Article ID 546409, 11 pages
doi:10.1155/2012/546409
Review Article
NewFormulationsof LocalAnaesthetics—Part I
EdwardA.Shipton
Department of Anaesthesia, University of Otago, Christchurch 8042, New Zealand
Correspondence should be addressed to Edward A. Shipton, shiptonea@xtra.co.nz
Received 26 July 2011; Revised 14 September 2011; Accepted 14 September 2011
Academic Editor: James B. Eisenkraft
Copyright © 2012 Edward A. Shipton. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Part 1 comments on the types of local anaesthetics (LAs); it provides a better understanding of the mechanisms of action of
LAs, and their pharmacokinetics and toxicity. It reviews the newer LAs such as levobupivacaine, ropivacaine, and articaine,
and examines the newer structurally diﬀerent LAs. The addition of adjuvants such as adrenaline, bicarbonate, clonidine, and
corticosteroidsisexplored.CommentismadeonthedeliveryoftopicalLAsviabioadhesiveplastersandgelsandcontrolled-release
local anaesthetic matrices. Encapulation matrices such as liposomes, microemulsions, microspheres and nanospheres, hydrogels
and liquid polymers are discussed as well. New innovations pertaining to LA formulations have indeed led to prolonged action
and to novel delivery approaches.
1.Introduction
Local anaesthetics (LAs) are used clinically for anaesthesia
and analgesia either following surgery or for management
of other acute and chronic pain conditions; they only last
a few hours. Part 1 of this paper deals with the newer LAs,
more recent LA formulations, a better understanding of the
mechanisms of action of LAs, and their pharmacokinetics
and toxicity.
Local anaesthesia for a prolonged period of days is
best provided using catheter techniques [1] with disposable
pumps [2] or multiple injections [3]. Most attempts to
prolong LA action have so far only doubled or tripled the
plain drug eﬀect time, using adjuncts to LA agents of readily
available agents. These include opioids and clonidine that
delay local anaesthetic clearance from their site of action
[4] and dexamethasone that prolongs peripheral nerve and
plexus blocks [5].
2.Typesof LocalAnaesthetics
Lignocaine is perhaps most commonly used or known local
anaesthetic agent; it is used either in local or regional anaes-
thesia, or in epidural or spinal blockade; it has a number
of uses in anaesthesia and pain medicine. However, it is
also given parenterally in the management of neuropathic
pain states. EMLA, a eutectic mixture of lignocaine and
prilocaine, is an eﬀective topical anaesthetic in preventing
pain associated with needle procedures [6].
Local anaesthetics canbe classiﬁedinto twogroups based
on the nature of the link, namely, amides [–NH–CO–] and
esters [–O–CO–] (Figures 1 and 2). The amide group is
the most commonly used clinically; it includes lignocaine,
prilocaine, levobupivacaine, bupivacaine, mepivacaine, and
ropivacaine.
The ester group is weak bases, solubilised for injection
as strong conjugate acidic hydrochloride salts (pH 3–6); it
includescocaine,procaine,chloroprocaine,andamethocaine
(Figure 3)[ 3, 7]. Benzocaine and butamben are ester-type
local anaesthetics mostly used in topical and mucous formu-
lations. Anaphylaxis to local anaesthetics is very uncommon
and has decreased in frequency because of the decreasing
use of the ester group of local anaesthetics [8]. Most allergic
reactions are due to the common metabolic product of
the ester local anaesthetic, para-amino benzoic acid [8].
Cross-reactivity among esters is common. Allergic reactions
to amide local anaesthetics remain anecdotal. Ingredients
included in local anaesthetic solutions such as antioxidants
or preservatives including metabisulphite or parabens (also
metabolised to para-amino benzoic acid) may also elicit
allergic or adverse reactions [8]. Local anaesthetics (without
preservatives or adrenaline) may be skin tested.2 Anesthesiology Research and Practice
3.Pharmacokinetics ofLocalAnaesthetics
Injectable local anaesthetics are subject to absorption; a large
fraction of the injected drug is removed by the systemic
circulation and distributed to distant organs according to
their vascular density [9]. Highly vascular organs (brain,
heart, lung, liver, and kidneys) are exposed to unmetabolised
local anaesthetic at peak concentration. The local anaesthetic
is taken up within each organ according to its tissue-
plasma partition coeﬃcient. Most absorbed local anaesthetic
is cleared from the liver. Hepatic clearance is a function
of the hepatic extraction ratio and hepatic blood ﬂow.
The hepatic extraction ratio, in turn, is dependent on the
ratio of free to protein-bound drug. Local anaesthetics
bind tightly to plasma proteins greatly limiting the free
fraction of available drug. Only the free or unbound fraction
that is bioactive. Like most weak bases, local anaesthetics
bind mainly to alpha-1-acid glycoprotein. Lignocaine, being
moderately protein-bound, has a high hepatic extraction
ratio (70–75% per pass) [9]. Clearance is therefore ﬂow-
limited and is reduced by factors that limit hepatic blood
ﬂow. Conversely, bupivacaine and ropivacaine, being highly
protein-bound, are cleared <50% per pass; hence, their
clearance depends on free drug concentration [9]. Low
cardiac output states may not greatly aﬀect the plasma
concentration of the highly protein-bound agents, as their
clearance is not ﬂow limited. Intrinsic hepatic disease may
alter clearance by altering plasma protein content and degree
of protein binding, by decreasing the enzyme activity of
the liver, and by reducing hepatic blood ﬂow. Patients with
liver disease may have single-shot blocks with normal doses.
Doses for continuous infusion and repeat blocks need to
be signiﬁcantly reduced (10–50% relative to the degree of
dysfunction) due to the risk of accumulation of the primary
compound and its metabolites [10]. Patients with mild or
controlled cardiac failure may not need a dose reduction for
single-shot blocks. Doses of ropivacaine and bupivacaine for
continuous infusion and repeat blocks need to be reduced, as
their metabolites will be eliminated slowly. In patients with
renaldysfunction,reducedclearanceandfasterabsorptionof
localanaestheticleadtoanelevationinplasmaconcentration
[10]. Clearance of both bupivacaine and ropivacaine has
been shown to be reduced in uraemic patients [9, 10]. The
clearance of one of the main metabolites of ropivacaine, 2,6-
pipecoloxylidide (PPX), is also decreased in uraemic patients
[9].
4.NewerLocalAnaesthetics
4.1. Levobupivacaine. In recent years, levobupivacaine, the
pure S (−) enantiomer of bupivacaine, emerged as a safer
alternative for regional anaesthesia than its racemic parent
(Figure 4). In common to all local anaesthetics, levobupiva-
cainereversiblyblocksthetransmissionofactionpotentialin
sensory, motor, and sympathetic nervous ﬁbres by inhibiting
thepassageofsodiumthroughvoltage-sensitiveionchannels
in the neuronal membrane. Various factors such as site
of administration, duration of continuous infusion, and/or
addition of agents with vasomotor eﬀect may inﬂuence the
degree of systemic uptake of levobupivacaine.
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Figure 1: Structure of all local anaesthetics.
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Figure 2: Amide local anaesthetics.
In pharmacodynamic studies, levobupivacaine demon-
strated less aﬃnity and depressant eﬀects on myocardial and
central nervous vital centres and a superior pharmacokinetic
proﬁle [11]. Clinically, levobupivacaine is well tolerated in
a variety of regional anaesthesia techniques both after bolus
administration and continuous postoperative infusion.
The incidence of adverse events with levobupivacaine
was similar to that after bupivacaine in comparative trials.
Theseincludehypotension,nausea,postoperativepain,fever,
vomiting, pruritus, back pain, headache, constipation, dizzi-
ness, and foetal distress [11]. The early clinical presentation
of toxicity after levobupivacaine appears to consist of cen-
tral nervous symptoms (disorientation, drowsiness, slurred
speech), which may culminate with tonic-clonic seizures in
some cases. Reports of toxicity with levobupivacaine are
scarce; occasional toxic symptoms are usually reversible with
minimal treatment with no fatal outcome [11].
Surgical sensory block of similar characteristics and re-
covery over equal dose ranges of levobupivacaine and bu-
pivacaine has been conﬁrmed in surgical patients [11].
The onset of motor block is slower with levobupivacaine,
and its quality follows the rank of order bupivacaine >
levobupivacaine>ropivacaine [11]. The regression of motor
block was signiﬁcantly more rapid after levobupivacaine and
ropivacaine than bupivacaine; this may be advantageous for
early ambulation after day-case surgery.
The eﬀective dose of epidural levobupivacaine for con-
tinuouspostoperativeanalgesiaapproaches15mg/hour[11].
The addition of adjunctive agents (adrenaline, opioids, or
clonidine) to levobupivacaine in epidural anaesthesia and
analgesia may increase the duration and quality of analgesia
and further decrease the risk of toxicity. Traditionally, the
dose of levobupivacaine used for spinal anaesthesia is 15mgAnesthesiology Research and Practice 3
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Figure 4: Structure of levobupivacaine.
[11]. Smaller doses (5–10mg) have been used in ambulatory
surgery and allow a more rapid recovery and subsequent
discharge home.
Current evidence suggests a potency hierarchy of bupiva-
caine>levobupivacaine>ropivacaineforepiduralsinlabour
[11]. Using an epidural bolus of 10mL levobupivacaine
0.2%–0.25% followed by epidural infusions or top-ups of
low concentrations levobupivacaine (0.1%–0.125%) pro-
vides the same good-quality labour analgesia as bupivacaine,
but possibly with less motor block [11]. A combined spinal-
epidural technique with intrathecal levobupivacaine 1.2–
2.5mg combined with a small dose of opioid (e.g., fentanyl
12.5–25μg) provides excellent prolonged sensory block with
minimum motor blockade [11].
In brachial plexus nerve blocks, a sensory and motor
block of similar onset (6–10min) and duration (14–16
hours) follows the administration of an equal dose of
levobupivacaine 0.5% or bupivacaine 0.5% [11]. Continuing
the administration of levobupivacaine via a peripheral
nerve block continuous catheter is associated with excellent
postoperative analgesia as demonstrated by a signiﬁcant
decline in the postoperative systemic opioids requirements.
4.2. Ropivacaine. Ropivacaine is a long-acting, enantiomer-
ically pure (S-enantiomer) amide local anaesthetic regional
anaesthetic with an eﬃcacy broadly similar to that of
bupivacaine (Figure 5). However, it may be a preferred
option because of its reduced central nervous system (CNS)
and cardiotoxic potential and its lower propensity for motor
block [12]. It has a high pKa and low lipid solubility that
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Figure 5: Structure of S and R enantiomers of ropivacaine
(marketed as the S enantiomer).
block nerve ﬁbres involved in pain transmission (A delta and
C ﬁbres) to a greater degree than those controlling motor
function (A beta ﬁbres). The drug is less cardiotoxic than
equal concentrations of racemic bupivacaine but more so
than lignocaine; it has a signiﬁcantly higher threshold for
CNS toxicity than racemic bupivacaine. Extensive clinical
data have shown that epidural ropivacaine 0.2% is eﬀective
for the initiation and maintenance of labour analgesia, and
provides pain relief after abdominal or orthopaedic surgery
especially when given in conjunction with opioids [12].
Ropivacaine had an adverse event proﬁle similar to that
of bupivacaine in clinical trials. Comparative data suggest
that higher concentrations of ropivacaine (0.75%) may be4 Anesthesiology Research and Practice
needed to provide the same sensory and motor blockade
as bupivacaine 0.5% [12]. Brachial plexus anaesthesia was
broadly similar to that achieved with equivalent volumes of
bupivacaine 0.5%, although the time to onset of sensory
block tended to be faster and the duration of motor block
shorter with ropivacaine [12].
4.3. Articaine. Articaine is a relatively new local anaesthetic
used now in dentistry in many countries. It is an amide type
local anaesthetic, and, instead of benzene ring, it contains
a thiophene ring that increases its lipid solubility. Unlike
other local anaesthetics, articaine is exceptional in that it
containsanadditionalestergroupthatisrapidlymetabolised
by plasma esterase to articainic acid [13]. As a result, its
half-life, about 20 minutes, is also very short compared
to other local anaesthetics. Thus, it can rapidly be cleared
from the systemic circulation through kidney, minimising
adverse eﬀects [13]. Advantages are low lipid solubility,
high plasma protein binding rate, fast metabolism, fast
elimination half time, and low blood levels [14]. Articaine
seems to be the local anaesthetic of ﬁrst choice in tissues with
suppurative inﬂammation, for adults, children (over 4 years
old), elderly, pregnant women, breastfeeding women, and
patients suﬀering from hepatic disorders and renal function
impairment [14]. Articaine solutions must not be used in
persons who are allergic or hypersensitive to sulphite, due to
thecontentofsodiummetabisulphiteasthevasoconstrictor’s
antioxidant in it.
4.4. Newer Structurally Diﬀerent Local Anaesthetics. Another
group of potent LAs includes the basic esters of phenylcar-
bamicacid[15].Basicestersofalkoxy-substitutedphenylcar-
bamic acid have shown high LA potency, while maintaining
a relatively safe toxicity proﬁle [15]. The most potent
phenylcarbamic anaesthetics exceed the potency of the most
common clinically used local anaesthetics by 100–300 times
[15]. Their potency uniquely increases with the decreasing
pH of the external medium. This is of importance when
using LAs in inﬂamed tissues, where the action of common
LAs is often problematic. Further study of their action is
required.
5. Mechanisms of Action of Local Anaesthetics
Local anaesthetics directly block transmission of pain from
nociceptive aﬀerents. Local anaesthetic agents are applied
directly, and their eﬃcacy results from action on the
nerve where the inward Na+ current is blocked at the
sodium ionophore during depolarisation. LAs not only
block Na+ channels but Ca2+ and K+ channels [16–18],
transient receptor potential vanniloid-1 receptors [19], and
other ligand-gated receptors as well. Local anaesthetics also
disrupt the coupling between certain G proteins and their
associated receptors [20]. Through this action, LAs exert
potent anti-inﬂammatory eﬀects, particularly on neutrophil
priming reactions [21]. Local anaesthetics inhibit local
inﬂammatory response to injury that can sensitise noci-
ceptive receptors and contribute to pain and hyperalgesia.
Studies have observed that local anaesthetics reduce the
release of inﬂammatory mediators from neutrophils, reduce
neutrophil adhesion to the endothelium, reduce formation
of free oxygen radicals, and decrease oedema formation [22].
There are, in addition, a variety of other antithrombotic
and neuroprotective actions of intravenous LAs [20] that are
independent of Na+ channel blockade but may account for
many of the improvements in pain after surgery [16, 22].
Local anaesthetics can alleviate some types of neuropathic
pain, and part of this eﬀect may be related to sensitisation
of the antinociceptive pain pathways that occur in the
neuropathic pain state; spinal glial cells have been shown to
play some part in this as well [23].
L i g n o c a i n es e e m st oh a v es o m em o d u l a t o r ye ﬀect on the
NMDA receptor [24]. Intravenous application of lignocaine
in a rat model of acute and neuropathic pain demonstrated
antinociception in both pain models [25]. Several studies
have previously shown that lignocaine at antiarrhythmic
doses or lower doses demonstrates neuroprotective eﬀects
[24]. A randomised, double blinded, placebo controlled
study of neuroprotection with lignocaine in cardiac surgery
showed a potential protective eﬀect of lower lignocaine doses
in nondiabetic patients. LAs have long been known to inhibit
thegrowthofdiﬀerentspeciesinvitro[24].Theantibacterial
activity of various LAs and additives used in epidural
infusions has been tested [26]. Bupivacaine was shown to
have the most eﬃcient activity against microorganisms [26].
L A sh a v eb e e nu s e dt oe n h a n c eb o w e lf u n c t i o nr e c o v e r y
after surgery or trauma. Twenty-two patients scheduled for
elective bowel surgery randomised into two groups were
given intravenous lignocaine or placebo to assess diﬀerences
in surgical pain, length of postsurgical ileus, and hospital
stay [27]. The lignocaine group showed less pain after
24 hours, a faster return of bowel movements, and an
earlier discharge from hospital. LAs stimulate the activity
of natural killer cells during the perioperative period [24].
Perioperative lignocaine has been found to improve imme-
diate postoperative pain management and reduce surgery-
induced immune alterations [28]. The long-term eﬀect of
anaesthesia/analgesia provided by LAs on cancer recurrence
needs further investigation.
6.LocalAnaestheticToxicity
Toxicity primarily involves the central nervous system fol-
lowed by the cardiovascular system. More potent agents
(bupivacaine, levobupivacaine, ropivacaine) produce car-
diotoxic eﬀects at lower blood concentrations and doses
than less potent LA agents (lignocaine) [29]. The (+)-
(R)-enantiomers bind with greater aﬃnity to cardiac Na+
channels than the (−)-(S)-enantiomers do. LA agents cause
marked but reversible lesions to skeletal muscle tissue
[3]. Myotoxicity seems to be explained by mitochondrial
bioenergetics alteration. In the animal model, this toxic
eﬀect was signiﬁcantly more severe in young rats [30]. The
nitric oxide pathway is involved in the development of
tachyphylaxis [31]. In addition, there is a growing amount of
evidence that intra-articular administration of bupivacaineAnesthesiology Research and Practice 5
is chondrotoxic especially at a higher concentration and with
prolonged exposure [24].
A lipid emulsion infusion alongside cardiopulmonary
resuscitation appears to be an eﬀective treatment for cardiac
toxicity induced by lipophilic medications [32]. The practice
advisory on LA systemic toxicity of the American Society
of Regional Anesthesia and Pain Medicine suggests that
20% lipid emulsion initially be administered as a bolus
of 1.5mL/kg over a minute [33]. Following completion of
the bolus, a continuous infusion of 0.25mL/kg/min should
be started [33, 34]. If the patient does not respond to
the initial bolus, one to two additional boluses may be
administered. The rate of the infusion may be increased
to 0.5mL/kg if there is persistent hypotension. The infu-
sion should be continued until 10 minutes after the
patient regains haemodynamic stability [33, 34]. Given
the diﬃculties of performing clinical trials, further labo-
ratory investigation and clinical correlation are needed to
better deﬁne its role in resuscitation. Another potential
treatment is the use of pegylated anionic liposomes to
reduce free drug concentration of LA [35]. In summary,
LA cardiotoxicity primarily arises from a blockade of
sodium channels. As for treatment, in addition to ventila-
tion, oxygenation, and chest compressions, lipid emulsion
therapy should be a primary element in the treatment
[36].
6.1. Prevention of Local Anaesthetic Toxicity. There is no sin-
gle measure that can prevent LA toxicity in clinical practice.
The lowest eﬀective dose of local anaesthetic should be used
(dose = product of volume × concentration). LAs should be
injectedincrementallythrougha catheter[33].Theneedleor
catheter should be carefully aspirated before each injection
with close observation when injecting LA. More dilute
LAs should be used. The use of ultrasound guidance may
reduce the frequencyof intravascular injection. Intravascular
injection of adrenaline 10–15 microgram/mL in adults
produces a >10 beat heart rate increase or a >15-mm Hg
systolic blood pressure increase in the absence of beta-
blockade, active labour, advanced age, or general/neuraxial
anaesthesia [33]. Intravascular injection of adrenaline
0.5 microgram/mL in children produces a >15-mmHg
increase in systolic blood pressure [33]. All these mea-
sures have improved morbidity and mortality following LA
use.
7. Adjuvants
Adrenaline induces vasoconstriction, reducing local anaes-
thetic clearance from the site of action, thus prolonging the
duration of action. Solutions such as 1:200000 or 1:400000
are commonly used [37].
The addition of bicarbonate raises the pH of LA solution
thereby increasing the proportion of unionised LA available
to cross the neuronal phospholipid membrane, increasing
speed of onset. The recommended dose is 1mL of 8.4% of
sodium bicarbonate per 10mL of LA. The stability of LAs
with added bicarbonate is not well studied; such mixtures
cannotberecommendedforcontinuousperineuralinfusions
[37].
Clonidine is an alpha-2 receptor agonist whose eﬀect
may be mediated by inhibiting action potentials. Its eﬀect is
dose dependent, increasing the duration of anaesthesia and
analgesia when used with intermediate acting LAs [37].
CorticosteroidshavebeenshowntospeciﬁcallyinhibitC-
ﬁbre transmission [38]. Dexamethasone prolongs peripheral
nerve and plexus blocks [5]. It prolongs analgesia from
interscalene blocks using ropivacaine or bupivacaine [39],
and prolongs the duration of analgesia after supraclavicular
brachial plexus blockade using mepivacaine [40].
8.Topical LocalAnaesthetics
Topical delivery systems for LA are characteristically com-
posed by a diversity of formulations (viscosity inducing
agents, preservatives, permeation enhancers, emollients,)
andpresentationssuchassemisolid(gel,creams,ointments),
liquid (emulsions, dispersions), and solid (patches) phar-
maceutical forms [41]. The proposed formulations aim to
reduce the LA concentration used, increase its permeability
and absorption, keep the LA at the target site for longer and
decrease the clearance, and limit local and systemic toxicity
[41].
8.1. Bioadhesive Plaster and Gels. Diﬀerent topical local
anaesthetics have varying eﬀects on skin blood ﬂow and
vascular reactivity. The vasoactive properties of 70mg ligno-
caine/70mg tetracaine medicated plaster (Rapydan), a new
topical local anaesthetic, were compared with those of tetra-
cainebase(4.0%w/worAmetop)and2.5%lignocaine/2.5%
prilocaine(EMLA)creamsin20healthyvolunteers[42].The
tetracaine base produced a greater degree of vasodilatation
than that seen after the application of a lignocaine/tetracaine
medicated plaster [42]. The eutectic patch will be discussed
further on.
In the laboratory, the anaesthetic action of the for-
mulated mepivacaine gel containing enhancer and vaso-
constrictor was evaluated with the tail-ﬂick analgesimeter
[43]. Among the enhancers used, polyoxyethylene 2-oleyl
ether showed the greatest enhancement of permeation.
The vasoconstrictor tetrahydrozoline showed prolonged and
increased local anaesthetic action compared to the control
used [43]. Mepivacaine gel is not available commercially
for use in humans. Mepivacaine’s spinal use was largely
abandonedinthelate1990sduetoarelativelyhighincidence
oftransientneurologicalsymptomswithconcentratedmepi-
vacaine solutions [44].
8.2. Controlled-Release Local Anaesthetic Matrix. An ab-
sorbable, controlled-release lignocaine matrix delivery sys-
tem has been developed; it is a suspension of a water-
insoluble particulate and a hydrophobic carrier containing
16% lignocaine (w/w) (Xybrex ) [45]. It can block the rat
sciatic nerve for 1-2 days and suppress postincisional pain
[16].6 Anesthesiology Research and Practice
Liposomes
Figure 6: Liposomes.
9. EncapsulationMatrices
A rapidly growing research topic is the use of vesicular
carriers such as liposomes, niosomes, ethosomes (soft lipid
vesicles), and elastic and deformable vesicles to provide an
eﬃcient dermal delivery system [46]. Encapsulation of local
anaesthetic agents allows large doses to be released slowly
and provides analgesia over a prolonged period without
toxicity [47]. Encapsulating agents include liposomes [48],
lipospheres [49], cyclodextrins [50], and microparticles [51].
Following injection of a depot of the formulation, much of
the LA agent is bound or carried inside another agent and
is not immediately available. The duration of the analgesia
depends on the release rate of the LA agent from the
carrier agent. Several properties such as hydrophobicity and
internal membrane pH aﬀect encapsulated drug release rates
[3]. Some synergistic agents such as dexamethasone and
clonidine encapsulated with the main eﬀective agent have
been formulated; these increased the anaesthesia time for
several days [3, 52].
9.1. Liposomes. Liposomes act as reservoirs for drugs. Lipid
vesicles are sealed sacs containing a lipid bilayer, usually
phospholipids (Figure 6).There arethree types ofliposomes,
namely, multilamellar vesicles, small unilamellar vesicles,
and large unilamellar vesicles [3]. Lipid-soluble drugs can
be carried in the bilayer itself; liposomes may contain one
or more bilayers. Alternatively, aqueous drugs can be carried
insidetheaqueouscompartmentcontainedinsidethebilayer
[53].
Liposomes supply both a lipophilic region and an aque-
ous “milieu interior” in one system making them suitable
for hydrophobic, aliphatic, and hydrophilic drugs (Figure 7)
aqueous ﬂuid
Lipid
Lipid soluble
drug in
Drug crystallized in
bilayer
bilayer
Figure 7: Liposome for drug delivery.
[54]. They are biocompatible due to their biodegradability
and low toxicity. Liposomes help to reduce exposure of
sensitive tissues to toxic drugs. They can be administered
by a variety of routes (topical, intramuscular, subcutaneous,
pulmonary, nasal, oral, and intravenous) [54]. Their route
of administration and their lipid composition size can
manipulate their pharmacokinetics and in vivo distribution.
Following a single injection at the time of surgery, they
remain in subcutaneous tissues (around the surgical inci-
sion) around a neural plexus or in the epidural space for a
much longer period of time compared to the free drug [54].
Liposomes suﬀer lack of reliability and reproducibility
during manufacture owing to oxidation and hydrolysis,
which results in leaking of the encapsulated drug [3, 55].
Liposome metabolite compounds have been found to be
neurotoxic. The mechanism for this may be lethicin fatty
acid oxidation. Also, uncontrolled leakage of drug may occur
following breakdown of the liposomes. Ideally, desirable
attributes should include prolonged analgesic action; no
neurotoxicity; sterility; physical and chemical stability giving
a long shelf life; absence of unwanted side products (e.g.,
residues of organic solvents in bilayer); a reproducible
production process [54].
Liposomal formulations of various anaesthetics allow an
increase in clinical eﬃcacy in comparison with the plain
drugs [56]. Recently, classical liposomes have evolved to
“highly deformable” liposomes, endowed with enhanced
skin penetration ability and drug skin delivery [57]. “Highly
deformable” liposomes consist of phospholipids and an edge
activator that is often a single chain surfactant which desta-
bilises the liposomal lipid bilayers, increasing their elasticity
and ﬂexibility [58] .S e v e r a ls t u d i e sh a v ed e m o n s t r a t e dt h e
penetrationacrosstheskinofliposomalvesiclestobedirectly
related with their deformability. The high adaptability of
such elastic vesicles enable them to squeeze between theAnesthesiology Research and Practice 7
cells of the stratum corneum to penetrate intact to the deep
layers of the skin; this gives an eﬀect comparable to that of a
subcutaneous injection [59].
Limitations of encapsulated local anaesthetic agents
include neurotoxicity, myotoxicity, tachyphylaxis, motor
block, and viscosity [3]. Many formulations including poly-
mer and liposome carriers have facilitated prolonged local
anaesthetic action for several days, although few clinical
studies have been performed. Many routes of drug admin-
istration have been described, including central neuraxial
administration and peripheral nerve administration [3].
Grant et al. [60] described safe and prolonged analgesia
for 48 hours following local anaesthetic inﬁltration of 2%
liposomal lignocaine. Boogaerts et al. [61]d e m o n s t r a t e da
twofold increase in the duration of the analgesia following
epidural administration of liposomal bupivacaine in patients
following abdominal surgery. For intraoral topical anaes-
thesia, liposome-encapsulated 2% ropivacaine gel was as
eﬀective as 20% benzocaine gel in reducing pain during nee-
dle insertion and inducing soft-tissue anaesthesia; neither,
however, was able to induce pulpal anaesthesia [62]. In a
recent randomised single-blinded, placebo-controlled (2.5%
lignocaine/2.5% prilocaine) cross-over study, liposomal-
encapsulated ropivacaine formulations (1%, 2%) did not
reduce the pain of insertion of a needle into the palatal
mucosa [63]. Another blinded cross-over study in volunteers
undergoing intraoral injections at four diﬀerent sessions
evaluated the injection discomfort comparing 2% and 3%
liposome-encapsulated mepivacaine with 2% mepivacaine
with 1:100,000 adrenaline and 3% mepivacaine [64]. The
encapsulation of mepivacaine was found to increase the
duration of anaesthesia and reduce the injection discom-
fort caused by these vasoconstrictor-associated formulations
[64].
The entrapment of hydrophobic drugs in the aqueous
core of liposomes as soluble inclusion complexes with
cyclodextrins has been proposed to avoid the use of organic
solvents, giving rise to drug-in cyclodextrin-in liposome
systems [65]. The main types of cyclodextrin are α-, β-,
and γ-cyclodextrins, comprising six to eight sugar units
in the ring. This combined approach that simultaneously
exploits the cyclodextrin solubilising power towards the
drugs and the liposome carrier function through the skin has
recently been demonstrated by using both classic [66]a n d
deformable liposomes [67]. The use of this double-loading
technique by preparing liposomes loaded with the plain
drug in the lipophilic phase and its cyclodextrin complex in
the aqueous phase of the vesicles gives rise to a fast onset
action and a prolonged eﬀect [68]. The composition vesicles
containing the cationic surfactant allowed a signiﬁcant (P<
0.05) improvement of the drug anaesthetic eﬀect in terms of
intensity and duration of action [68].
9.2. Microemulsions. Microemulsions have penetration-
enhancing properties. Local anaesthetics encapsulated in
microemulsions result in fast transdermal penetration and
eﬀect [39, 69]. Microemulsions contain a large amount of
surfactants and cosurfactants that have the potential to cause
haemolysis or histopathological changes [69].
Microsphere
Liposome
Figure 8: Microspheres (or nanospheres) within liposome.
9.3. Poly(lactic-co-glycolic acid) Microspheres and Nano-
spheres. The most commonly used micro- and nanoscale
vehicles for drug encapsulation and delivery are micro-
spheres and nanospheres. They are usually prepared from
biodegradable synthetic hydrophobic materials such as
homo- or copolymers of polylactic and polyglycolic acids
[70].
Microparticles are perfect for drug delivery as they
remain at the depot site for long periods allowing slow
prolonged release of the encapsulated drug [3]. Particle size
and the thickness of thin, free ﬁlms are factors in drug
release. The lipospheres are stable structures consisting of
a solid hydrophobic fat core such as triglycerides or fatty
acid derivatives, estabilised by a monolayer of phospholipids
(Figure 8)[ 3].
More recently, a nanoliposphere has been developed
that does not gelify and is suitable for injection [3, 71].
When poly(dL-lactic acid) microspheres were embedded
into poloxamer 407-based hydrogel, this microsphere-gel
system containing lignocaine was easy to inject. In addition,
it proved degradable [3]. Clinically, in human intercostal
blockade studies, dexamethasone added to microcapsules
containing bupivacaine showed longer duration of anaesthe-
sia aﬀect compared with microcapsules without dexametha-
sone [3].
9.4. Hyaluronic Acid-Based Hydrogels. Hyaluronic acid is a
nonimmunogenic naturally occurring mucopolysaccharide
used as a viscous carrier solution to prolong LA action [3].
However, addition of cross-linked hyaluronic acid doubled
the length of action of bupivacaine compared with the
noncross-linked hyaluronic acid. It is in an easily injectable
liquid form.
9.5. Calcium Phosphate Apatite Loaded with Bupivacaine.
Synthetic calcium-deﬁcient apatites are structurally similar
to biological apatites; they are chemical precursors of bipha-
sic calcium phosphates. Biphasic calcium phosphates are
mixtures of hydroxyapatite and beta-tricalcium phosphate
and are widely used as bone substitutes in human surgery
[72]. In Wistar male rats, bupivacaine has been loaded8 Anesthesiology Research and Practice
on to calcium-deﬁcient apatites using isostatic compaction
[72]. This was able to release local anaesthetic in a manner
that prevented or limited postoperative pain following bone
surgery [72].
9.6. Controlled-Release Local Anaesthetic Matrix. As previ-
ously mentioned, the absorbable, controlled-release, local
anaesthetic delivery system containing 16% (w/w) ligno-
caine (Xybrex) is capable of providing up to several days
of reversible rat sciatic nerve block in a dose- (mass-)
dependent fashion [73]. Two sets of lignocaine-containing
drug delivery matrices (OSB-L and OST-R) have been used
in subfascial sciatic nerve blocks in rats as well. The OSB-
L formulations consisted of four diﬀerent concentrations
of lignocaine ranging from 1.875% to 15% (w/w). These
are denoted as OSB-1.875L, OSB-3.75L, OSB-7.5L, and
OSB- 15L [73]. The OST-R formulations consisted of four
diﬀerent concentrations of the drug release rate modiﬁer,
ranging from 5% to 20% (w/w) in 5% increments, with
lignocaine concentration kept constant at 16% (w/w). These
formulations are denoted OST-5R, OST-10R, OST-15R, and
OST-20R [73]. All OSB-L formulations produced complete
and reversible, dose-dependent blockade of nociceptive and
motor functions [73]. Blockade by OST-R formulations
varied with the concentration of the release rate modiﬁer.
All formulations gave complete, reversible blocks of both
functions; importantly, their durations did not change
monotonically with increasing concentrations of the release
rate modiﬁer [73]. Implants of slow-release lignocaine
formulations are most eﬀective against postincisional pain
when placed at the ipsilateral nerve innervating the area
of incision [74] .N oh u m a ns t u d i e so fi t su s eh a v eb e e n
published as yet.
9.7.InjectableLiquid Polymers. Therearethreetypes ofpoly-
mers for encapsulation, namely, nondegradable polymers,
synthetic polymers, natural biodegradables (that degrade
to nontoxic products that are completely eliminated from
the body), and drug-conjugated polymers (where a drug is
attached to water-soluble polymer by a cleavable bond) [3].
The drug-polymer conjugate can be directly targeted to the
site of speciﬁc action. The use of a 15% bupivacaine lactic
acid-co-castor oil copolymer prolonged the in vivo eﬀect to
96-hour sensory block [75].
Injectable polymers are simple and reliable to prepare;
simple mixing combines the local anaesthetic. The main
disadvantage is the prolonged time these polymer carriers
dwell in the injection site, far beyond the time of the eﬀect
of the local anaesthetic agent [3]. The safety and tissue
compatibility of biodegradable pasty polymers have been
tested and found to be safe with no systemic tissue damage
or polymer-related lesions [3, 76].
9.8. Films. One of the key areas of intense research is there-
fore to achieve an optimal and desirable controlled and sus-
tained drug release from the use of biodegradable ﬁlms. The
buccal route has some unique compelling beneﬁts making it
worth trying; such beneﬁts include avoiding ﬁrst pass eﬀect,
easy accessibility, and better patient compliance. Adhesion of
buccaladhesivedrugdeliverydevicestomucosalmembranes
leads to an increased drug concentration gradient at the
absorption site and therefore improved bioavailability of sys-
temically delivered drugs [77]. Various bioadhesive mucosal
dosage forms have been developed as ﬁlms. An ideal buccal
ﬁlm should be ﬂexible, elastic, and soft, with accepted size
and thickness, yet adequately strong to withstand breakage
due to stress from mouth activities. It must also possess
good bioadhesive strength so that it can be retained in the
mouth for a desired duration [78]. It should be nonirritant,
not cause teeth discoloration, resistant to metabolism, and
be capable of releasing a drug at appropriate rate. Buccal
ﬁlmsweredevelopedusingcarbopol 971Pasamucoadhesive
polymer and glycerol as a plasticizer. In testing, a buccal
mucoadhesive ﬁlm using lignocaine and its hydrochloride
salt as a model drug found that drug concentration aﬀected
the mucoadhesive properties of the ﬁlms [79].
A slow-release lignocaine sheet has been produced and
has been used for sciatic nerve block in the rat model
of postoperative pain. Single treatment of this controlled-
releaselignocaineinhibitedhyperalgesiaandc-fosexpression
in the spinal cord dorsal horn for one week without inducing
inﬂammation of the sciatic nerve [80]. Bioadhesive ﬁlms
containing benzocaine have been tested in the rat model for
benzocaine local delivery [81]. Tail-ﬂick tests have shown the
duration of benzocaine-induced analgesia to be signiﬁcantly
prolonged with the ﬁlms compared to commercial creams
[81].
10. Conclusion
Local anaesthetics are widely used to manage acute, chronic,
andcancerpain,foranaesthesia,andfordiagnosticpurposes.
Local anaesthetics may have similar chemical structures,
but diﬀering pharmacokinetic properties and spectra of
pharmacodynamic eﬀects. This inﬂuences the selection of
agents for use in various clinical situations [82]. New
innovations pertaining to LA formulations lead to prolonged
action or to novel delivery approaches. Decades after the
introduction of local anaesthetics for analgesia/anaesthesia,
new properties may still be discovered. New applications of
thisclassofdrugsmaystillbeanticipated.Theuseofregional
anaesthesia may aﬀect cancer recurrence rates following
surgical resection of tumours via immunomodulation [79].
The preservation of the body’s immune processes by local
anaesthetics needs to be further studied.The development of
new eﬀective delivery systems should suitably modulate the
release rate of these drugs, extend their anaesthetic eﬀect,
and enhance their localisation; this should reduce problems
of systemic toxicity. Part 2 of this paper will deal with new
techniques for the delivery of topical and injectable local
anaesthetics.
Disclosure
No beneﬁts in any form have been or will be received from a
commercial party related directly or indirectly to the subject
of this paper.Anesthesiology Research and Practice 9
Conﬂict of Interests
The author declares that there is no conﬂict of interests.
References
[1] S.A.Grant,K.C.N ielsen,R.A.Greengrass,S.M.Steele,andS.
M. Klein, “Continuous peripheral nerve block for ambulatory
surgery,” Regional Anesthesia and Pain Medicine, vol. 26, no. 3,
pp. 209–214, 2001.
[2] S. M. Klein, S. A. Grant, R. A. Greengrass et al., “Interscalene
brachial plexus block with a continuous catheter insertion
system and a disposable infusion pump,” Anesthesia and
Analgesia, vol. 91, no. 6, pp. 1473–1478, 2000.
[3] C. F. Weiniger, M. Golovanevski, M. Sokolsky-Papkov, and A.
J.Domb,“Reviewofprolongedlocalanestheticaction,” Expert
Opinion on Drug Delivery, vol. 7, no. 6, pp. 737–752, 2010.
[ 4 ]P .S .H o d g s o n ,J .M .N e a l ,J .E .P o l l o c k ,a n dS .S .L i u ,“ T h e
neurotoxicity of drugs given intrathecally (Spinal),” Anesthesia
and Analgesia, vol. 88, no. 4, pp. 797–809, 1999.
[5] P. A. Vieira, I. Pulai, G. C. Tsao, P. Manikantan, B. Kelle, and
N. R. Connelly, “Dexamethasone with bupivacaine increases
duration of analgesia in ultrasound-guided interscalene
brachialplexusblockade,”EuropeanJournalofAnaesthesiology,
vol. 27, no. 3, pp. 285–288, 2010.
[ 6 ]J .A .L a n d e r ,B .J .W e l t m a n ,a n dS .S .S o ,“ E M L Aa n d
amethocaine for reduction of children’s pain associated with
needle insertion,” Cochrane Database of Systematic Reviews
(Online), vol. 3, Article ID CD004236, 2006.
[7] M. O. Columb and K. MacLennan, “Local anaesthetic agents,”
Anaesthesia and Intensive Care Medicine, vol. 8, no. 4, pp. 159–
162, 2007.
[8] P. Dewachter, C. Mouton-Faivre, and C. W. Emala, “Ana-
phylaxis and anesthesia: controversies and new insights,”
Anesthesiology, vol. 111, no. 5, pp. 1141–1150, 2009.
[9] D. Dillane and B. T. Finucane, “Local anesthetic systemic
toxicity,” Canadian Journal of Anesthesia,v o l .5 7 ,n o .4 ,p p .
368–380, 2010.
[10] P. H. Rosenberg, B. T. Veering, and W. F. Urmey, “Maximum
recommended doses of local anesthetics: a multifactorial
concept,” Regional Anesthesia and Pain Medicine, vol. 29, no.
6, pp. 564–575, 2004.
[11] C. L. Burlacu and D. J. Buggy, “Update on local anesthetics:
focus on levobupivacaine,” Therapeutics and Clinical Risk
Management, vol. 4, no. 2, pp. 381–392, 2008.
[12] K. J. McClellan and D. Faulds, “Ropivacaine: an update of its
use in regional anaesthesia,” Drugs, vol. 60, no. 5, pp. 1065–
1093, 2000.
[13] E. H. Mojumdar and A. P. Lyubartsev, “Molecular dynamics
simulations of local anesthetic articaine in a lipid bilayer,”
Biophysical Chemistry, vol. 153, no. 1, pp. 27–35, 2010.
[14] N. Nizharadze, M. Mamaladze, N. Chipashvili, and D.
Vadachkoria, “Articaine—the best choice of local anesthetic in
contemporary dentistry,” Georgian Medical News, no. 190, pp.
15–23, 2011.
[15] V. Vegh, J. Cizmarik, and K. Hahnenkamp, “Is there a place
for local anesthetics structurally diﬀerent from classical amid
or ester local anesthetics?” Current Opinion in Anaesthesiology,
vol. 19, no. 5, pp. 509–515, 2006.
[16] C. F. Wang, C. Pancaro, P. Gerner, and G. Strichartz, “Pro-
longed suppression of postincisional pain by a slow-release
formulation of lidocaine,” Anesthesiology, vol. 114, no. 1, pp.
135–149, 2011.
[17] X. Guo, N. A. Castle, D. M. Chernoﬀ, and G. R. Strichartz,
“Comparative inhibition of voltage-gated cation channels by
local anesthetics,” Annals of the New York Academy of Sciences,
vol. 625, pp. 181–199, 1991.
[18] Z. Xiong and G. R. Strichartz, “Inhibition by local anesthetics
of Ca2+ channels in rat anterior pituitary cells,” European
Journal of Pharmacology, vol. 363, no. 1, pp. 81–90, 1998.
[19] K. Hirota, D. Smart, and D. G. Lambert, “The eﬀects of local
and intravenous anesthetics on recombinant rat VR1 vanilloid
receptors,” Anesthesia and Analgesia, vol. 96, no. 6, pp. 1656–
1660, 2003.
[20] M. W. Hollmann, D. Strumper, S. Herroeder, and M. E.
Durieux, “Receptors, G proteins, and their interactions,”
Anesthesiology, vol. 103, no. 5, pp. 1066–1078, 2005.
[21] M. W. Hollmann, A. Gross, N. Jelacin, and M. E. Durieux,
“Local anesthetic eﬀects on priming and activation of human
neutrophils,” Anesthesiology, vol. 95, no. 1, pp. 113–122, 2001.
[ 2 2 ]A .K a b a ,S .R .L a u r e n t ,B .J .D e t r o ze ta l . ,“ I n t r a v e n o u sl i d o -
caineinfusionfacilitatesacuterehabilitationafterlaparoscopic
colectomy,” Anesthesiology, vol. 106, no. 1, pp. 11–18, 2007.
[23] I. Power, “An update on analgesics,” British Journal of Anaes-
thesia, vol. 107, no. 1, pp. 19–24, 2011.
[24] A. Borgeat and J. Aguirre, “Update on local anesthetics,”
CurrentOpinioninAnaesthesiology,vol.23,no.4,pp.466–471,
2010.
[ 2 5 ]U .M u t h - S e l b a c h ,H .H e r m a n n s ,J .U .S t e g m a n ne ta l . ,
“Antinociceptive eﬀects of systemic lidocaine: involvement of
the spinal glycinergic system,” European Journal of Pharmacol-
ogy, vol. 613, no. 1–3, pp. 68–73, 2009.
[26] M. W. Coghlan, M. J. Davies, C. Hoy, L. Joyce, R. Kilner,
and M. J. Waters, “Antibacterial activity of epidural infusions,”
Anaesthesia and Intensive Care, vol. 37, no. 1, pp. 66–69, 2009.
[27] K. P. Harvey, J. D. Adair, M. Isho, and R. Robinson, “Can
intravenous lidocaine decrease postsurgical ileus and shorten
hospital stay in elective bowel surgery? A pilot study and
literature review,” American Journal of Surgery, vol. 198, no.
2, pp. 231–236, 2009.
[28] I. Z. Yardeni, B. Beilin, E. Mayburd, Y. Levinson, and H.
Bessler, “The eﬀect of perioperative intravenous lidocaine on
postoperative pain and immune function,” Anesthesia and
Analgesia, vol. 109, no. 5, pp. 1464–1469, 2009.
[29] C. W. Clarkson and L. M. Hondeghem, “Mechanism for
bupivacaine depression of cardiac conduction: fast block
of sodium channels during the action potential with slow
recovery from block during diastole,” Anesthesiology, vol. 62,
no. 4, pp. 396–405, 1985.
[30] K. Nouette-Gaulain, C. Dadure, D. Morau et al., “Age-
dependent bupivacaine-induced muscle toxicity during con-
tinuous peripheral nerve block in rats,” Anesthesiology, vol.
111, no. 5, pp. 1120–1127, 2009.
[ 3 1 ]R .T .W i l d e r ,M .G .S h o l a s ,a n dC .B .B e r d e ,“ N ( G ) - n i t r o -
L-arginine methyl ester (L-NAME) prevents tachyphylaxis to
local anesthetics in a dose-dependent manner,” Anesthesia and
Analgesia, vol. 83, no. 6, pp. 1251–1255, 1996.
[32] G. Weinberg, R. Ripper, D. L. Feinstein, and W. Hoﬀman,
“Lipid emulsion infusion rescues dogs from bupivacaine-
induced cardiac toxicity,” Regional Anesthesia and Pain
Medicine, vol. 28, no. 3, pp. 198–202, 2003.
[33] J.M.Neal,C.M.Bernards,J.F.Butterworthetal.,“ASRAprac-
tice advisory on local anesthetic systemic toxicity,” Regional
AnesthesiaandPainMedicine,vol.35,no.2,pp.152–161,2010.
[34] P. Toledo, “The role of lipid emulsion during advanced cardiac
life support for local anesthetic toxicity,” International Journal
of Obstetric Anesthesia, vol. 20, no. 1, pp. 60–63, 2011.10 Anesthesiology Research and Practice
[35] B. A. Howell and A. Chauhan, “Bupivacaine binding to
pegylated liposomes,” Anesthesia and Analgesia, vol. 109, no.
2, pp. 678–682, 2009.
[36] J. W. Wolfe and J. F. Butterworth, “Local anesthetic systemic
toxicity: update on mechanisms and treatment,” Current
Opinion in Anaesthesiology, vol. 24, no. 5, pp. 561–566, 2011.
[37] W. C. Culp Jr. and W. C. Culp, “Practical application of local
anesthetics,” Journal of Vascular and Interventional Radiology,
vol. 22, no. 2, pp. 111–118, 2011.
[ 3 8 ]B .A .W i l l i a m s ,B .B .M u r i n s o n ,B .R .G r a b l e ,a n dS .L .O r e -
baugh, “Future considerations for pharmacologic adjuvants
in single-injection peripheral nerve blocks for patients with
diabetes mellitus,” Regional Anesthesia and Pain Medicine, vol.
34, no. 5, pp. 445–457, 2009.
[39] K. C. Cummings, D. E. Napierkowski, I. Parra-Sanchez et
al., “Eﬀect of dexamethasone on the duration of interscalene
nerve blocks with ropivacaine or bupivacaine,” British Journal
of Anaesthesia, vol. 107, no. 3, pp. 446–453, 2011.
[40] S. J. Parrington, D. O’Donnell, V. W. S. Chan et al., “Dex-
amethasone added to mepivacaine prolongs the duration
of analgesia after supraclavicular brachial plexus blockade,”
Regional Anesthesia and Pain Medicine, vol. 35, no. 5, pp. 422–
426, 2010.
[41] E. de Paula, C. M. S. Cereda, G. R. Tofoli, M. Franz-Montan,
L. F. Fraceto, and D. R. De Ara´ ujo, “Drug delivery systems
for local anesthetics,” Recent Patents on Drug Delivery and
Formulation, vol. 4, no. 1, pp. 23–34, 2010.
[42] M. D. Wiles, S. A. Dobson, and I. K. Moppett, “The eﬀect of a
new topical local anaesthetic delivery system on forearm skin
blood ﬂow reactivity,” Anaesthesia, vol. 65, no. 2, pp. 178–183,
2010.
[43] C.-W. Cho, J.-S. Choi, and S.-C. Shin, “Enhanced local
anesthetic action of mepivacaine from the bioadhesive gels,”
Pakistan Journal of Pharmaceutical Sciences, vol. 24, no. 1, pp.
87–93, 2011.
[44] J. G. F¨ orster and P. H. Rosenberg, “Revival of old local
anesthetics for spinal anesthesia in ambulatory surgery,”
CurrentOpinioninAnaesthesiology,vol.24,no.6,pp.633–637,
2011.
[45] C.F.Wang,A.G.Djalali,A.Gandhietal.,“Anabsorbablelocal
anesthetic matrix provides several days of functional sciatic
nerve blockade,” Anesthesia and Analgesia, vol. 108, no. 3, pp.
1027–1033, 2009.
[46] C. Sinico and A. M. Fadda, “Vesicular carriers for dermal drug
delivery,” Expert Opinion on Drug Delivery,v o l .6 ,n o .8 ,p p .
813–825, 2009.
[47] A. Shikanov, A. J. Domb, and C. F. Weiniger, “Long acting
local anesthetic-polymer formulation to prolong the eﬀect of
analgesia,”JournalofControlledRelease,vol.117,no.1,pp.97–
103, 2007.
[48] J.G.Boogaerts,N.D.Lafont,S.Carlinoetal.,“Biodistribution
of liposome-associated bupivacaine after extradural adminis-
tration to rabbits,” British Journal of Anaesthesia, vol. 75, no. 3,
pp. 319–325, 1995.
[49] M. D. Blanco, M. V. Bernardo, C. G´ omez, E. Mu˜ niz, and J.
M. Teij´ on, “Bupivacaine-loaded comatrix formed by albumin
microspheres included in a poly(lactide-co-glycolide) ﬁlm: in
vivo biocompatibility and drug release studies,” Biomaterials,
vol. 20, no. 20, pp. 1919–1924, 1999.
[50] G. Dollo, D. O. Thompson, P. Le Corre, F. Chevanne,
and R. Le Verge, “Inclusion complexation of amide-typed
local anesthetics with β-cyclodextrin and its derivatives. III.
Biopharmaceutics of bupivacaine-SBE7-βCD complex follow-
ing percutaneous sciatic nerve administration in rabbits,”
International Journal of Pharmaceutics, vol. 164, no. 1-2, pp.
11–19, 1998.
[51] J. Curley, J. Castillo, J. Hotz et al., “Prolonged regional nerve
blockade: injectable biodegradable bupivacaine/polyester
microspheres,” Anesthesiology, vol. 84, no. 6, pp. 1401–1410,
1996.
[52] C. Dr¨ ager, D. Benziger, F. Gao, and C. B. Berde, “Prolonged
intercostal nerve blockade in sheep using controlled-release
of bupivacaine and dexamethasone from polymer micro-
spheres,” Anesthesiology, vol. 89, no. 4, pp. 969–979, 1998.
[53] T. Lian and R. J. Y. Ho, “Trends and developments in liposome
drug delivery systems,” Journal of Pharmaceutical Sciences, vol.
90, no. 6, pp. 667–680, 2001.
[54] S. A. Grant, “The Holy Grail: long-acting local anaesthetics
and liposomes,” Best Practice and Research: Clinical Anaesthe-
siology, vol. 16, no. 2, pp. 345–352, 2002.
[55] G. J. Grant, Y. Barenholz, B. Piskoun, M. Bansinath, H.
Turndorf, and E. M. Bolotin, “DRV liposomal bupivacaine:
preparation, characterization, and in vivo evaluation in mice,”
Pharmaceutical Research, vol. 18, no. 3, pp. 336–343, 2001.
[56] P. Mura, F. Maestrelli, M. L. Gonz´ alez-Rodr´ ıguez, I.
Michelacci, C. Ghelardini, and A. M. Rabasco, “Development,
characterization and in vivo evaluation of benzocaine-loaded
liposomes,” European Journal of Pharmaceutics and Biophar-
maceutics, vol. 67, no. 1, pp. 86–95, 2007.
[57] G. Cevc, A. Sch¨ atzlein, and H. Richardsen, “Ultradeformable
lipid vesicles can penetrate the skin and other semi-permeable
barriers unfragmented. Evidence from double label CLSM
experiments and direct size measurements,” Biochimica et
Biophysica Acta, vol. 1564, no. 1, pp. 21–30, 2002.
[58] M. M. A. Elsayed, O. Y. Abdallah, V. F. Naggar, and N.
M. Khalafallah, “Lipid vesicles for skin delivery of drugs:
reviewing three decades of research,” International Journal of
Pharmaceutics, vol. 332, no. 1-2, pp. 1–16, 2007.
[59] G. M. El Maghraby, B. W. Barry, and A. C. Williams, “Lipo-
somes and skin: from drug delivery to model membranes,”
European Journal of Pharmaceutical Sciences, vol. 34, no. 4-5,
pp. 203–222, 2008.
[60] G. J. Grant, Y. Barenholz, E. M. Bolotin et al., “A novel
liposomal bupivacaine formulation to produce ultralong-
acting analgesia,” Anesthesiology, vol. 101, no. 1, pp. 133–137,
2004.
[61] J. G. Boogaerts, N. D. Lafont, A. G. Declercq et al., “Epidural
administration of liposome-associated bupivacaine for the
management of postsurgical pain: a ﬁrst study,” Journal of
Clinical Anesthesia, vol. 6, no. 4, pp. 315–320, 1994.
[62] M. Franz-Montan, E. De Paula, F. C. Groppo, A. L. R.
Silva, J. Ranali, and M. C. Volpato, “Liposome-encapsulated
ropivacaineforintraoraltopicalanesthesia,”OralSurgery,Oral
Medicine, Oral Pathology, Oral Radiology and Endodontology,
vol. 110, no. 6, pp. 800–804, 2010.
[ 6 3 ]M .F r a n z - M o n t a n ,E .d eP a u l a ,F .C .G r o p p o ,A .L .R .S i l v a ,
J. Ranali, and M. C. Volpato, “Liposomal delivery system for
topical anaesthesia of the palatal mucosa,” British Journal of
Oral and Maxillofacial Surgery. In press.
[64] G. R. Tofoli, C. M. S. Cereda, F. C. Groppo et al., “Eﬃcacy of
liposome-encapsulated mepivacaine for inﬁltrative anesthesia
in volunteers,” Journal of Liposome Research,v o l .2 1 ,n o .1 ,p p .
88–94, 2011.
[ 6 5 ]F .M a e s t r e l l i ,M .L .G o n z ´ alez-Rodr´ ıguez, A. M. Rabasco,
C. Ghelardini, and P. Mura, “New ”drug-in cyclodextrin-in
deformable liposomes” formulations to improve the thera-
peutic eﬃcacy of local anaesthetics,” International Journal of
Pharmaceutics, vol. 395, no. 1-2, pp. 222–231, 2010.Anesthesiology Research and Practice 11
[66] M.C.B.Lira,M.S.Ferraz,D.G.V.C.daSilvaetal.,“Inclusion
complex of usnic acid with β-cyclodextrin: characterization
and nanoencapsulation into liposomes,” Journal of Inclusion
Phenomena and Macrocyclic Chemistry, vol. 64, no. 3-4, pp.
215–224, 2009.
[67] A. Gillet, A. Grammenos, P. Comp` ere, B. Evrard, and G. Piel,
“Development of a new topical system: drug-in-cyclodextrin-
in-deformable liposome,” International Journal of Pharmaceu-
tics, vol. 380, no. 1-2, pp. 174–180, 2009.
[68] M. Bragagni, F. Maestrelli, N. Mennini, C. Ghelardini, and
P. Mura, “Liposomal formulations of prilocaine: eﬀect of
complexation with hydroxypropyl-ß-cyclodextrin on drug
anesthetic eﬃcacy,” Journal of Liposome Research, vol. 20, no.
4, pp. 315–322, 2010.
[69] C. X. He, Z. G. He, and J. Q. Gao, “Microemulsions as
drug delivery systems to improve the solubility and the
bioavailability of poorly water-soluble drugs,” Expert Opinion
on Drug Delivery, vol. 7, no. 4, pp. 445–460, 2010.
[70] P. Le Corre, J. H. Rytting, V. Gajan, F. Chevanne, and R. Le
Verge, “In vitro controlled release kinetics of local anaesthetics
from poly(D,L-lactide) and poly(lactide-co-glycolide) micro-
spheres,”JournalofMicroencapsulation,vol.14,no.2,pp.243–
255, 1997.
[71] J. Pietkiewicz, M. Sznitowska, and M. Placzek, “The expulsion
of lipophilic drugs from the cores of solid lipid microspheres
in diluted suspensions and in concentrates,” International
Journal of Pharmaceutics, vol. 310, no. 1-2, pp. 64–71, 2006.
[72] E. Verron, O. Gauthier, P. Janvier et al., “Analgesic properties
of calcium phosphate apatite loaded with bupivacaine on
postoperative pain,” Journal of Biomedical Materials Research
B, vol. 94, no. 1, pp. 89–96, 2010.
[73] P. Gerner, C. F. Wang, B. S. Lee et al., “The relationship
between functional sciatic nerve block duration and the rate
of release of lidocaine from a controlled-release matrix,”
Anesthesia and Analgesia, vol. 111, no. 1, pp. 221–229, 2010.
[74] C. F. Wang, C. Pancaro, P. Gerner, and G. Strichartz, “Pro-
longed suppression of postincisional pain by a slow-release
formulation of lidocaine,” Anesthesiology, vol. 114, no. 1, pp.
135–149, 2011.
[75] M. Sokolsky-Papkov, L. Golovanevski, A. J. Domb, and C.
F. Weiniger, “Prolonged local anesthetic action through slow
release from poly(lactic acid co castor oil),” Pharmaceutical
Research, vol. 26, no. 1, pp. 32–39, 2009.
[76] B. Vaisman, M. Motiei, A. Nyska, and A. J. Domb, “Bio-
compatibility and safety evaluation of a ricinoleic acid-based
poly(ester-anhydride) copolymer after implantation in rats,”
Journal of Biomedical Materials Research A,v o l .9 2 ,n o .2 ,p p .
419–431, 2010.
[77] Y. Sudhakar, K. Kuotsu, and A. K. Bandyopadhyay, “Buccal
bioadhesive drug delivery—a promising option for orally less
eﬃcient drugs,” Journal of Controlled Release, vol. 114, no. 1,
pp. 15–40, 2006.
[78] A. K. Singla, M. Chawla, and A. Singh, “Potential applications
of carbomer in oral mucoadhesive controlled drug delivery
system: a review,” Drug Development and Industrial Pharmacy,
vol. 26, no. 9, pp. 913–924, 2000.
[79] R. Abu-Huwaij, S. Assaf, M. Salem, and A. Sallam, “Mucoad-
hesive dosage form of lidocaine hydrochloride: I. Mucoadhe-
siveandphysicochemicalcharacterization,”DrugDevelopment
and Industrial Pharmacy, vol. 33, no. 8, pp. 855–864, 2007.
[80] M. Tobe, H. Obata, T. Suto et al., “Long-term eﬀect of sciatic
nerve block with slow-release lidocaine in a rat model of
postoperative pain,” Anesthesiology, vol. 112, no. 6, pp. 1473–
1481, 2010.
[81] D.R.DeAraujo,C.Padula,C.M.S.Ceredaetal.,“Bioadhesive
ﬁlms containing benzocaine: correlation between in vitro
permeationandinvivolocalanestheticeﬀect,”Pharmaceutical
Research, vol. 27, no. 8, pp. 1677–1686, 2010.
[82] J. E. Heavner, “Local anesthetics,” Current Opinion in Anaes-
thesiology, vol. 20, no. 4, pp. 336–342, 2007.